SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics

We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain.

Press release:

June 9, 2021 – Utrecht, the Netherlands

SentryX, a spin-off of the University Medical Center Utrecht (the Netherlands) today announced that it raised €3.2M in seed funding for the development of their next-generation pain relief therapeutic platform. The round includes an investment from the Utrecht Health Seed Fund.

Every year, millions of people in Europe and the US undergo a significant orthopedic surgical procedure and experience intense post-operative pain as a result. Despite the application of systemic pain medication, most patients still report insufficient pain relief, hampering post-operative recovery. SentryX’s innovative pain relief therapy platform focuses on minimizing post-operative pain to improve the overall patient experience and quality of care.

Bas Oosterman, CEO of SentryX comments: “Our initial results are promising and underscore the potential of our platform to provide superior pain relief. In speaking with orthopedic surgeons worldwide, we are convinced that our platform can make a big impact. We are excited to have the support of our investors in realizing our next development steps.”

Albert van Wijck, anesthesiologist and pain specialist at the University Medical Center Utrecht states: “SentryX is doing important work that addresses an unmet need. Orthopedic surgeries are among the most painful procedures, especially the first day after surgery, despite state-of-the-art analgesic therapy. Pain is not only uncomfortable for the patient, but it also induces complications such as thrombosis, infection, and a prolonged recovery.”

Jaap de Bruin, Fund Manager of UHSF commented: “We are delighted to support the SentryX team in further developing their pain medication platform. We believe that the platform has great potential to lower the burden of pain and medication directly after surgery, benefitting both patients and healthcare systems. This aligns with the vision of UHSF and we look forward to working with SentryX’s outstanding team.”

 

Background statements

About SentryX

SentryX is a life sciences company based in Utrecht, the Netherlands, that develops next-generation pain relief therapeutics. SentryX was founded by Prof. dr. J.J. Verlaan and Dr. B.J. Oosterman and spun out of the University Medical Center Utrecht, the Netherlands.

For more information, please visit https://www.sentryx.nl.

 

About Utrecht Health Seed Fund

Utrecht Health Seed Fund (UHSF) is an early-stage life sciences & health investment fund also based in Utrecht, the Netherlands. It focuses on scalable technologies in the fields of Life Sciences (therapeutics and diagnostics), Medical Devices, Digital Health, and Animal Health in the earliest stages of development.

UHSF was established by Utrecht Holdings with the assistance and support of the European Regional Development Fund (ERDF), UMC Utrecht, and the University of Utrecht.

For more information, please visit www.uhsf.nl.

 

 

Contact information

Dr. Christiaan de Koning, christiaan.dekoning@sentryx.nl